The PCSK9i revolution: important changes to PBS eligibility

These next-generation lipid therapies may see more patients benefit, say experts

Clinical studies on the PCSK9 inhibitor class show they dramatically lower LDL-C levels – by an average of up to 60% – when combined with other lipid lowering therapies such as statins and cholesterol absorption inhibitors.

LDL-C test

Data from the FOURIER and ODYSSEY cardiovascular outcomes trials show PCSK9 inhibitors can lower the risk of serious CV events such as myocardial infarction, strokes, and revascularisations, as well as